Trial Profile
A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 28 May 2014 New trial record